RESULTS
depressive, cancer pain, anxiety, pain
TUMOR PROGRESSION, SOLID TUMORS
Between August 5, 2019 and June 30, 2020, a total of 116 patients from the oncology and pain departments of Xinhua Hospital Affiliated to Shanghai Jiao Tong University Medical College were screened, of whom 32 refused to sign informed consent or met at least one exclusion criterion for this trial. Finally, 83 patients with solid tumors who met the conditions were randomized into groups (No.: L‐TAMS group 42 vs. Placebo group 41). All patients completed the final follow‐up of this study. No data loss occurred during this trial except for 10 patients who died due to tumor progression (No.: L‐TAMS Group 6 vs. Placebo Group 4), whose data were also included in the final outcome analysis according to ITT principles (Figure CONSORT flow diagram of the study participants. ITT, intention‐to‐treatBaseline characteristics of the patientsAbbreviations: BMI, body mass index; BTcP, breakthrough cancer pain; Che, chemotherapy; GAD‐7, generalized anxiety disorder‐7; OMEDD, oral morphine equivalent daily dose; PHQ‐9, patient health questionnaire‐9; Rad, radiotherapy; VAS, visual analogue scale.VAS:0–10, higher scores reveal more intense pain.PHQ‐9:0–27, higher scores reveal more severe depressive symptoms.GAD‐7:0–21, higher scores reveal more severe anxiety symptoms.